Chronic Gastritis Clinical Trial
— MCEOfficial title:
Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial
Verified date | July 2015 |
Source | Changhai Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
A new Magnetic-controlled Capsule Endoscopy (MCE) was developed by ANKON and got SFDA's approval in China in 2013. It has recently been evaluated to compare the diagnostic accuracy of MCE with that of standard gastroscopy for gastric diseases in 70 patients with encouraging results (In Press). To further testify the diagnostic accuracy of MCE for both the diffuse and focal diseases in stomach, we performed this single-blinded multi-center prospective study compared MCE with gastroscopy in patients with gastric symptoms and indication for upper GI Endoscopy.
Status | Completed |
Enrollment | 350 |
Est. completion date | February 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients presented with gastric symptoms and ready for the first Upper GI endoscopy - Patients with known focal gastric diseases: gastric ulcer, gastric polyps, early gastric cancer, gastric stromal tumors and so on. - Age of 18 years to 70 years Exclusion Criteria: - Patients with impaired bowel movement from ileus or organic digestive diseases - Patients with known large and obstructing tumors of the upper GI tract - Patients after upper GI surgery or abdominal surgery altering GI anatomy - Patients under full anticoagulation - Patient in poor general condition - Patients using equipment that may be affected by radio transmission - Patients using equipment that may be affected by magnetic field - Pregnancy or suspected pregnancy |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
China | Shanghai Changhai Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital | Chinese PLA General Hospital, General Hospital of Beijing PLA Military Region, Nanfang Hospital of Southern Medical University, Peking Union Medical College Hospital, RenJi Hospital, Shandong Provincial Hospital, Wuhan Union Hospital, China |
China,
Liao Z, Duan XD, Xin L, Bo LM, Wang XH, Xiao GH, Hu LH, Zhuang SL, Li ZS. Feasibility and safety of magnetic-controlled capsule endoscopy system in examination of human stomach: a pilot study in healthy volunteers. J Interv Gastroenterol. 2012 Oct;2(4):155-160. Epub 2012 Oct 1. — View Citation
Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest Endosc. 2010 Feb;71(2):280-6. doi: 10.1016/j.gie.2009.09.031. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects diagnosed with gastric diffuse lesions by MCE Versus Standard Gastroscopy | 2 days | No | |
Primary | Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy | 2 days | No | |
Secondary | Volume of water and drugs used for gastric preparation | 1 hour | No | |
Secondary | Scores of the cleanliness of stomach after preparation | 1 day | No | |
Secondary | Percentage of patients in whom there was complete visualization of the gastric surface in the antrum, body, and fundus and identification of the cardia and pylorus | 1 day | No | |
Secondary | Examination times of MCE and standard gastroscopy | 1 day | No | |
Secondary | Patient acceptance of MCE and standard gastroscopy | 3 days | No | |
Secondary | Adverse events of both procedures | 2 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04066530 -
A Study to Evaluate the Efficacy and Safety of AD-203
|
Phase 3 | |
Recruiting |
NCT05048069 -
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
|
||
Completed |
NCT01817556 -
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.
|
Phase 4 | |
Recruiting |
NCT01813812 -
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
|
Phase 3 | |
Completed |
NCT00996788 -
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
|
Phase 3 | |
Completed |
NCT04341454 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
|
Phase 3 | |
Enrolling by invitation |
NCT05021029 -
A Study of Pre-Malignant Gastric Conditions
|
||
Completed |
NCT05073614 -
Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis
|
N/A | |
Completed |
NCT04697186 -
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Recruiting |
NCT00455806 -
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
|
Phase 3 | |
Recruiting |
NCT05666531 -
Research on Innovative Diagnosis and Treatment System of Syndrome Differentiation of Zang-fu Viscera and Effectiveness Evaluation Based on Inter-Arm Blood Pressure Measured Simultaneously
|
||
Completed |
NCT03847753 -
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
|
||
Completed |
NCT04189705 -
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
|
Phase 3 | |
Completed |
NCT05014334 -
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
|
Phase 4 | |
Completed |
NCT02356679 -
Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients
|
Phase 4 | |
Completed |
NCT03609892 -
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
|
Phase 4 | |
Unknown status |
NCT02282670 -
A Study to Evaluate the Efficacy and Safety of DA-5204
|
Phase 3 | |
Completed |
NCT01119768 -
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
|
Phase 4 | |
Completed |
NCT02658864 -
Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
|
Phase 1 |